Skip to main content

New Products

  • FDA accepts Teva's sNDA for pediatric QNASL

    JERUSALEM — Teva Pharmaeceuticals on Tuesday announced that the Food and Drug Administration accepted the company's supplemental new drug application for a lower dose QNASL (beclomethasone dipropionate) nasal aerosol, which is used for the treatment of seasonal and perennial allergic rhinitis in children ages 4 years to 11 years.

    QNASL, a waterless intranasal corticosteroid spray, is currently available to treat patients 12 years of age and older who show symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the company notes.

  • Red Carpet Manicure launches new shades for summer

    HAUPPAUGE, N.Y. — Red Carpet Manicure nail care brand has announced the launch of “Sweet Indulgence,” a six-shade limited-edition collection of LED nail gel polishes for summer.

    The line is available now at RedCarpetManicure.com and will roll out in June at Ulta Beauty Stores and Ulta.com.
     
    The pastel palette draws inspiration directly from top designer fashion week shows and includes a range of warm hues like peach and lavender to trace elements of pink and sea foam tones.
     

  • Perrigo receives FDA approval for generic Astepro

    DUBLIN — Perrigo on Monday announced that it received approval from the Food and Drug Administration for azelastine hydrochloride nasal spray (0.15%), a generic version of Astepro.

    The prescription medicine is indicated for people ages 12 years and older and is used to treat nasal symptoms brought on by seasonal allergies or environmental irritants. Annual sales for the drug were approximately $97 million, according to Symphony Health Solutions

  • Bayer's Kogenate FS receives FDA approval

    WHIPPANY, N.J. — Bayer HealthCare on Monday announced that the Food and Drug Administration approved the company's new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

  • FDA approves Zontivity tabs

    SILVER SPRING, Md. — The Food and Drug Administration on Thursday approved Zontivity (vorapaxar) tablets, an anti-platelet agent that's designed to decrease the tendency of platelets to clump together to form a blood clot. Zontivity is the first in a new class of drugs called a protease-activated receptor-1 (PAR-1) antagonist, the agency said.

  • Telehealth provider Teladoc to accelerate growth with AmeriDoc acquisition

    DALLAS — Teladoc, a telehealth provider with more than 7.5 million members, has announced the acquisition of AmeriDoc, a telehealth company founded in 2007.

    Teladoc stated that the acquisition supports its strategy for growth into new and fast-growing market segments.

  • Banana Boat gears up for summer with launch of new products

    SHELTON, Conn. — Energizer Personal Care, the makers of Banana Boat brand sunscreen, announced the availability of four new products in mass grocery and drug retailers nationwide, including a formula designed specifically for men.

  • PreMama launches powdered prenatal multi

    PROVIDENCE, R.I. — PreMama last week announced the launch of a Target-exclusive: PreMama Complete, a prenatal vitamin formulated for women who are pregnant, breast feeding or trying to conceive.

X
This ad will auto-close in 10 seconds